What is claimed is:

1. A compound of the formula



, (I)



, (I)

R_a denotes a hydrogen atom or a methyl group,

R_b denotes a phenyl, benzyl or 1-phenylethyl group, wherein the phenyl core is substituted in each case by the groups R_1 to R_3, whilst

R_1 and R_2, which may be identical or different, each denote a hydrogen, fluorine, chlorine, bromine or iodine atom,

a methyl, ethyl, hydroxy, methoxy, ethoxy, amino, cyano, vinyl or ethynyl group,

an aryl, aryloxy, arylmethyl or arylmethoxy group,

a methyl or methoxy group substituted by 1 to 3 fluorine atoms or

R_1 together with R_2, if they are bound to adjacent carbon atoms, denote a -CH=CH-CH=CH-, -CH=CH-NH- or -CH=N-NH- group and

R_3 denotes a hydrogen, fluorine, chlorine or bromine atom,

R_c denotes a hydrogen atom or a methyl group,

X denotes a methyne group substituted by a cyano group or a nitrogen atom,

A denotes a 1,1- or 1,2-vinylene group, each of which may be substituted by one or two methyl groups or by a trifluoromethyl group,

an ethynylene group, or

a 1,3-butadien-1,4-ylene group optionally substituted by a methyl or trifluoromethyl group,

B denotes a hydrogen atom or a C_{1-4}-alkyl group, a methyl group substituted by 1 to 3 fluorine atoms, an ethyl group substituted by 1 to 5 fluorine atoms, a C_{1-4}-alkylcarbonyl, carboxy, C_{1-4}-alkoxycarbonyl, aminocarbonyl, C_{1-4}-alkylaminocarbonyl, di-(C_{1-4}-alkyl)-aminocarbonyl, pyrrolidinocarbonyl, piperidinocarbonyl, morpholinocarbonyl or a 4-(C_{1-4}-alkyl)-piperazinocarbonyl group, or

a C_{1-4}-alkyl group substituted by the group R_4, whilst

R_4 denotes a C_{1-4}-alkoxy group,

an amino group substituted by two C_{1-4}-alkyl groups, wherein the alkyl groups may be identical or different and each alkyl moiety may be substituted from position 2 by a C_{1-4}-alkoxy- or di-(C_{1-4}-alkyl)-amino group or by a 4- to 7-membered alkyleneimino group, whilst in the above-mentioned 6- to 7-membered alkyleneimino groups in each case a methylene group may be replaced in the 4-position by an oxygen or sulphur atom, by a sulphinyl, sulphonyl or N-(C_{1-4}-alkyl)-imino group,

a 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 methyl groups,

a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups, wherein in each case a methylene group in the 4-position is replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl or N-(C_{1-2}-alkyl)-imino group, or

an imidazolyl group optionally substituted by 1 to 3 methyl groups,

C denotes a C_{1-6}-alkylene group, a -O-C_{1-6}-alkylene group, whilst the alkylene moiety is linked to the group D, or an oxygen atom, which may not be linked to a nitrogen atom of the group D, and

D denotes a pyrrolidino group in which the two hydrogen atoms are replaced in the 2-position by a group E, wherein

E denotes a -CH_2-O-CO-CH_2-, -CH_2CH_2-O-CO-, -CH_2-O-CO-CH_2CH_2-, -CH_2CH_2-O-CO-CH_2- or -$CH_2CH_2CH_2$-O-CO- bridge optionally substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidino group in which the two hydrogen atoms are replaced in the 3-position by a group F, wherein

F denotes a -O-CO-CH_2CH_2-, -CH_2-O-CO-CH_2-, -CH_2CH_2-O-CO-, -O-CO-$CH_2CH_2CH_2$-, -CH_2-O-CO-CH_2CH_2-, -CH_2CH_2-O-CO-CH_2-, -$CH_2CH_2CH_2$-O-CO-, -O-CO-CH_2-NR_5-CH_2-, -CH_2-O-CO-CH_2-NR_5-, -O-CO-CH_2-O-CH_2- or -CH_2-O-CO-CH_2-O- bridge optionally substituted by one or two C_{1-2}-alkyl groups, whilst

R_5 denotes a hydrogen atom or a C_{1-4}-alkyl group,

a piperidino or hexahydroazepino group, wherein the two hydrogen atoms are replaced in the 2-position by a group E, where E is as hereinbefore defined,

a piperidino or hexahydroazepino group, wherein in each case the two hydrogen atoms in the 3-position or in the 4-position are replaced by a group F, where F is as hereinbefore defined,

a piperazino- or 4-(C_{1-4}-alkyl)-piperazino group, wherein the two hydrogen atoms in the 2-position or in the 3-position of the piperazino ring are replaced by a group E, where E is as hereinbefore defined,

a pyrrolidino or piperidino group, wherein two vicinal hydrogen atoms are replaced by a -O-CO-CH_2- -CH_2-O-CO-, -O-CO-CH_2CH_2-, -CH_2-O-CO-CH_2-, -CH_2CH_2-O-CO-, -O-CO-CH_2-NR_5- or -O-CO-CH_2-O- bridge optionally substituted by one or two C_{1-2}-alkyl groups, whilst R_5 is as hereinbefore defined and the heteroatoms of the above-mentioned bridges are not bound to the 2- or 5-position of the pyrrolidino ring and are not bound to the 2- or 6-position of the piperidino ring,

a piperazino or 4-(C_{1-4}-alkyl)-piperazino group, wherein a hydrogen atom in the 2-position together with a hydrogen atom in the 3-position of the piperazino ring are replaced by a -CH_2-O-CO-CH_2- or -CH_2CH_2-O-CO- bridge optionally substituted by one or two C_{1-2}-alkyl groups,

a piperazino group in which a hydrogen atom in the 3-position together with the hydrogen atom in the 4-position are replaced by a -CO-O-CH_2CH_2- or -CH_2-O-CO-CH_2- bridge optionally substituted by one or two C_{1-2}-alkyl groups, whilst in each case the left-hand end of the above-mentioned bridges is bound to the 3-position of the piperazino ring,

a pyrrolidino, piperidino or hexahydroazepino group substituted by the group R_6, wherein

R_6 denotes a 2-oxo-tetrahydrofuranyl, 2-oxo-tetrahydropyranyl, 2-oxo-1,4-dioxanyl or 2-oxo-4-(C_{1-4}-alkyl)-morpholinyl group optionally substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidino group substituted in the 3-position by a 2-oxo-morpholino group, whilst the 2-oxo-morpholino group may be substituted by one or two C_{1-2}-alkyl groups,

a piperidino or hexahydroazepino group substituted in the 3- or 4-position by a 2-oxo-morpholino group, whilst the 2-oxo-morpholino group may be substituted by one or two C_{1-2}-alkyl groups,

a 4-(C_{1-4}-alkyl)-piperazino or 4-(C_{1-4}-alkyl)-homopiperazino group substituted at a ring nitrogen atom by R_6, wherein R_6 is as hereinbefore defined,

a piperazino or homopiperazino group substituted in the 4- position by the group R_7, wherein

R_7 denotes a 2-oxo-tetrahydrofuran-3-yl, 2-oxo-tetrahydrofuran-4-yl, 2-oxo-tetrahydropyran-3-yl, 2-oxo-tetrahydropyran-4-yl or 2-oxo-tetrahydropyran-5-yl group optionally substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidino group substituted in the 3-position by a (R_5NR_7)-, R_7O-, R_7S-, R_7SO- or R_7SO_2- group, whilst R_5 and R_7 are as hereinbefore defined,

a piperidino or hexahydroazepino group substituted in the 3- or 4-position by a (R_5NR_7)-, R_7O-, R_7S-, R_7SO- or R_7SO_2- group, wherein R_5 and R_7 are as hereinbefore defined,

a pyrrolidino, piperidino or hexahydroazepino group substituted by a R_6-C_{1-4}-alkyl-, (R_5NR_7)-C_{1-4}-alkyl-, R_7O-C_{1-4}-

alkyl-, R_7S-C_{1-4}-alkyl-, R_7SO-C_{1-4}-alkyl-, R_7SO_2-C_{1-4}-alkyl- or (R_5NR_7)-CO- group, wherein R_5 to R_7 are as hereinbefore defined,

a pyrrolidino group substituted in the 3-position by a R_6-CO-NR_4, R_6-C_{1-4}-alkylene-$CONR_4$, (R_5NR_7)-C_{1-4}-alkylene-$CONR_5$, R_7O-C_{1-4}-alkylene-$CONR_5$, R_7S-C_{1-4}-alkylene-$CONR_5$, R_7SO-C_{1-4}-alkylene-$CONR_5$, R_7SO_2-C_{1-4}-alkylene-$CONR_5$, 2-oxo-morpholino-C_{1-4}-alkylene-$CONR_5$, R_6-C_{1-4}-alkylene-Y or C_{2-4}-alkyl-Y group, whilst the C_{2-4}-alkyl moiety of the C_{2-4}-alkyl-Y group is substituted in each case from position 2 by a (R_5NR_7)-, R_7O-, R_7S-, R_7SO- or R_7SO_2- group and the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups, wherein

R_5 to R_7 are as hereinbefore defined and

Y denotes an oxygen or sulphur atom, an imino, N-(C_{1-4}-alkyl)-imino, sulphinyl or sulphonyl group,

a piperidino- or hexahydroazepino group substituted in the 3- or 4-position by a R_6-CO-NR_5, R_6-C_{1-4}-alkylene-$CONR_5$, (R_5NR_7)-C_{1-4}-alkylene-$CONR_5$, R_7O-C_{1-4}-alkylene-$CONR_5$, R_7S-C_{1-4}-alkylene-$CONR_5$, R_7SO-C_{1-4}-alkylene-$CONR_5$, R_7SO_2-C_{1-4}-alkylene-$CONR_5$, 2-oxo-morpholino-C_{1-4}-alkylene-$CONR_5$, R_6-C_{1-4}-alkylene-Y or C_{2-4}-alkyl-Y group, wherein Y is as hereinbefore defined, the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups and the C_{2-4}-alkyl moiety of the C_{2-4}-alkyl-Y group is substituted in each case from position 2 by a (R_5NR_7)-, R_7O-, R_7S-, R_7SO- or R_7SO_2- group, whilst R_5 to R_7 are as hereinbefore defined,

a 4-(C_{1-4}-alkyl)-piperazino or 4-(C_{1-4}-alkyl)-homopiperazino group substituted at a ring nitrogen atom by a R_6-C_{1-4}-alkyl-, (R_5NR_7)-C_{1-4}-alkyl-, R_7O-C_{1-4}-alkyl-, R_7S-C_{1-4}-alkyl-, R_7SO-C_{1-4}-alkyl-, R_7SO_2-C_{1-4}-alkyl- or R_5NR_7-CO- group, wherein R_5 to R_7 are as hereinbefore defined,

a piperazino or homopiperazino group substituted in the 4- position by a R_6-C_{1-4}-alkyl-, R_6-CO-, R_6-C_{1-4}-alkylene-CO-, (R_5NR_7)-C_{1-4}-alkylene-CO-, R_7O-C_{1-4}-alkylene-CO-, R_7S-C_{1-4}-alkylene-CO-, R_7SO-C_{1-4}-alkylene-CO- or R_7SO_2-C_{1-4}-alkylene-CO- group, wherein R_5 to R_7 are as hereinbefore defined,

a piperazino or homopiperazino group substituted in the 4- position by a C_{2-4}-alkyl group, wherein the C_{2-4}-alkyl group is substituted in each case from position 2 by an (R_5NR_7)-, R_7O-, R_7S-, R_7SO- or R_7SO_2- group, whilst R_5 and R_7 are as hereinbefore defined,

a pyrrolidino, piperidino- or hexahydroazepino group substituted by a 2-oxo-morpholino-C_{1-4}-alkyl group, wherein the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidino group, substituted in the 3-position by a C_{2-4}-alkyl-Y group, wherein Y is as hereinbefore defined and the C_{2-4}-alkyl moiety of the C_{2-4}-alkyl-Y group is substituted in each case from position 2 by a 2-oxo-morpholino group optionally substituted by one or two C_{1-2}-alkyl groups,

a piperidino or hexahydroazepino group substituted in the 3- or 4-position by a C_{2-4}-alkyl-Y group, wherein Y is as hereinbefore defined and the C_{2-4}-alkyl moiety of the C_{2-4}-alkyl-Y group is substituted in each case from position 2 by a 2-oxo-morpholino group optionally substituted by one or two C_{1-2}-alkyl groups,

a 4-(C_{1-4}-alkyl)-piperazino- or 4-(C_{1-4}-alkyl)-homopiperazino group substituted at a ring nitrogen atom by a 2-oxo-morpholino-C_{1-4}-alkyl group, wherein the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a piperazino or homopiperazino group substituted in the 4- position by a 2-oxo-morpholino-C_{1-4}-alkylene-CO group, wherein the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a piperazino or homopiperazino group substituted in the 4- position by a C_{2-4}-alkyl group, wherein the C_{2-4}-alkyl moiety is substituted in each case from position 2 by a 2-oxo-morpholino group optionally substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidinyl or piperidinyl group substituted in the 1- position by the group R_7, by a R_6-C_{1-4}-alkyl-, R_6-CO-, R_6-C_{1-4}-alkylene-CO-, (R_5NR_7)-C_{1-4}-alkylene-CO-, R_7O-C_{1-4}-alkylene-CO-, R_7S-C_{1-4}-alkylene-CO-, R_7SO-C_{1-4}-alkylene-CO-, R_7SO_2-C_{1-4}-alkylene-CO- or 2-oxo-morpholino-C_{1-4}-alkylene-CO- group, wherein R_5 to R_7 are as hereinbefore defined and the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidinyl or piperidinyl group substituted in the 1- position by a C_{2-4}-alkyl group, wherein the C_{2-4}-alkyl moiety is substituted in each case from position 2 by a (R_5NR_7)-, R_7O-, R_7S-, R_7SO-, R_7SO_2- or 2-oxo-morpholino group, whilst R_5 and R_7 are as hereinbefore defined and the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidin-3-yl-NR_5, piperidin-3-yl-NR_5 or piperidin-4-yl-NR_5 group substituted at the ring nitrogen atom in each case by the group R_7, by a R_6-C_{1-4}-alkyl-, R_6-CO-, R_6-C_{1-4}-alkylene-CO-, (R_5NR_7)-C_{1-4}-alkylene-CO-, R_7O-C_{1-4}-alkylene-CO-, R_7S-C_{1-4}-alkylene-CO-, R_7SO-C_{1-4}-alkylene-CO-, R_7SO_2-C_{1-4}-alkylene-CO- or 2-oxo-morpholino-C_{1-4}-alkylene-CO- group, wherein R_5 to R_7 are as hereinbefore defined and the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a pyrrolidin-3-yl-NR_5, piperidin-3-yl-NR_5 or piperidin-4-yl-NR_5 group substituted in each case at the ring nitrogen atom by a C_{2-4}-alkyl group, wherein the C_{2-4}-alkyl moiety is substituted in each case from position 2 by a (R_5NR_7)-, R_7O-, R_7S-, R_7SO-, R_7SO_2- or 2-oxo-morpholino group, whilst R_5 and R_7 are as hereinbefore defined and the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a R_6-C_{1-4}-alkylene-NR_5 group in which R_5 and R_6 are as hereinbefore defined, or

a C_{2-4}-alkyl-NR_4 group, wherein the C_{2-4}-alkyl moiety is substituted in each case from position 2 by a (R_5NR_7)-, R_7O-, R_7S-, R_7SO-, R_7SO_2- or 2-oxo-morpholino group, whilst R_5 and R_7 are as hereinbefore defined and the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2}-alkyl groups,

a 2-oxo-morpholin-4-yl group substituted by the group R_8 or by the group R_8 and a C_{1-4}-alkyl group, whilst

R_8 denotes a C_{3-4}-alkyl, hydroxy-C_{1-4}-alkyl, C_{1-4}-alkoxy-C_{1-4}-alkyl, di-(C_{1-4}-alkyl)-amino-C_{1-4}-alkyl, pyrrolidino-C_{1-4}-alkyl, piperidino-C_{1-4}-alkyl, morpholino-C_{1-4}-alkyl, 4-(C_{1-4}-alkyl)-piperazino-C_{1-4}-alkyl, C_{1-4}-alkylsulphanyl-C_{1-4}-alkyl, C_{1-4}-alkylsulphinyl-C_{1-4}-alkyl, C_{1-4}-alkylsulphonyl-C_{1-4}-alkyl, cyan-C_{1-4}-alkyl, C_{1-4}-alkoxycarbonyl-C_{1-4}-alkyl, aminocarbonyl-C_{1-4}-alkyl, C_{1-4}-alkyl-aminocarbonyl-C_{1-4}-alkyl, di-(C_{1-4}-alkyl)-aminocarbonyl-C_{1-4}-alkyl, pyrrolidinocarbonyl-C_{1-4}-alkyl, piperidinocarbonyl-C_{1-4}-alkyl, morpholinocarbonyl-C_{1-4}-alkyl or a 4-(C_{1-4}-alkyl)-piperazinocarbonyl-C_{1-4}-alkyl group,

a 2-oxo-morpholin-4-yl group substituted by two groups R_8, whilst R_8 is as hereinbefore defined and the two groups R_8 may be identical or different,

a 2-oxo-morpholin-4-yl group in which the two hydrogen atoms of a methylene group are replaced by a -$(CH_2)_m$-, -CH_2-Y-CH_2-, -CH_2-Y-CH_2-CH_2-, -CH_2CH_2-Y-CH_2CH_2- or -CH_2CH_2-Y-$CH_2CH_2CH_2$- bridge optionally substituted by one or two C_{1-2}-alkyl groups, whilst

m denotes the number 2, 3, 4, 5 or 6 and
Y denotes an oxygen or sulphur atom, a sulphinyl, sulphonyl or C_{1-4}-alkylimino group,

a 2-oxo-morpholin-4-yl group in which a hydrogen atom in the 5-position together with a hydrogen atom in the 6-position is replaced by a -$(CH_2)_n$-, -CH_2-Y-CH_2-, -CH_2-Y-CH_2CH_2- or -CH_2-CH_2-Y-CH_2- bridge, whilst

Y is as hereinbefore defined and
n denotes the number 2, 3 or 4,

whilst, unless otherwise stated, the aryl moieties mentioned in the definitions of the above-mentioned groups denote a phenyl group which may be mono- or disubstituted by R_9, whilst the substituents may be identical or different and

R_9 denotes a fluorine, chlorine, bromine or iodine atom, a C_{1-2}-alkyl, trifluoromethyl or C_{1-2}-alkoxy group, or

two groups R_9, if they are bound to adjacent carbon atoms, together denote a C_{3-4}-alkylene, methylenedioxy or 1,3-butadien-1,4-ylene group,

or a tautomer or salt thereof.

2. A compound of the formula I according to claim 1, wherein

R_a denotes a hydrogen atom,

R_b denotes a 1-phenylethyl, 3-methylphenyl, 3-chlorophenyl, 3-bromophenyl or 3-chloro-4-fluorophenyl group,

R_c denotes a hydrogen atom,

X denotes a nitrogen atom,

A denotes a 1,2-vinylene or ethynylene group,

B denotes a hydrogen atom,

C denotes an -O-CH_2CH_2-, -O-$CH_2CH_2CH_2$- or -O-$CH_2CH_2CH_2CH_2$- group, whilst the alkylene moiety in each case is linked to the group D, and

D denotes a piperidino group in which the two hydrogen atoms in the 4-position are replaced by a -CH_2-O-CO-CH_2, -CH_2CH_2-O-CO-, -CH_2CH_2-O-CO-CH_2-, -O-CO-CH_2-NCH_3-CH_2- or -O-CO-CH_2-O-CH_2-bridge,

a piperazino group in which a hydrogen atom in the 3-position together with the hydrogen atom in the 4-position are replaced by a -CO-O-CH_2-CH_2- or -CH_2-O-CO-CH_2- bridge, whilst in each case the left-hand ends of the above-mentioned bridges are bound to the 3-position of the piperazino ring,

a piperidino group which is substituted in the 4-position by a 2-oxo-morpholino or 2-oxo-morpholinomethyl group, whilst the 2-oxo-morpholino moiety may be substituted in each case by one or two methyl groups,

a piperazino group which is substituted in the 4-position by a 2-oxo-tetrahydrofuran-3-yl- or 2-oxo-tetrahydrofuran-4-yl group,

a piperidino group which is substituted in the 4-position by a R_6S group, whilst

R_6 denotes a 2-oxo-tetrahydrofuran-3-yl or 2-oxo-tetrahydrofuran-4-yl group,

a piperazino group which is substituted in the 4-position by a 2-oxo-tetrahydrofuranylmethyl or 2-oxo-tetrahydrofuranyl-carbonyl group,

a piperazino group which is substituted in the 4-position by a [2-(2-oxo-tetrahydrofuran-3-ylsulphenyl)ethyl] group,

a piperidin-4-yl group which is substituted in the 1-position by a 2-oxo-tetrahydrofuran-3-yl or 2-oxo-tetrahydrofuran-4-yl group,

a 2-oxo-morpholin-4-yl group which is substituted by a methoxymethyl or methoxyethyl group,

a 2-oxo-morpholin-4-yl group in which the two hydrogen atoms of a methylene group are replaced by a $-CH_2CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2CH_2-$, $-CH_2-O-CH_2CH_2-$ or $-CH_2CH_2-O-CH_2CH_2-$ bridge,

or a tautomer or salt thereof.

3. A compound of the formula I according to claim 1, wherein

R_a denotes a hydrogen atom,

R_b denotes a 1-phenylethyl or 3-chloro-4-fluorophenyl group,

R_c denotes a hydrogen atom,

X denotes a nitrogen atom,

A denotes a 1,2-vinylene group,

B denotes a hydrogen atom,

C denotes an $-O-CH_2CH_2-$, $-O-CH_2CH_2CH_2-$ or $-O-CH_2CH_2CH_2CH_2-$ group, whilst the alkylene moiety in each case is linked to the group D, and

D denotes a piperazino group which is substituted in the 4- position by a 2-oxo-tetrahydrofuran-4-yl or 2-oxo-tetrahydrofuran-5-ylcarbonyl group,

or a tautomer or salt thereof.

4. A compound selected from the group consisting of:

(1) 4-[(3-chloro-4-fluorophenyl)amino]-7-{3-[4-(2-oxo-tetrahydrofuran-4-yl)-piperazin-1-yl]-propyloxy}-6-[(vinylcarbonyl)amino]-quinazoline,

(2) 4-[(3-chloro-4-fluorophenyl)amino]-7-(2-{4-[(*S*)-(2-oxo-tetrahydrofuran-5-yl)carbonyl]-piperazin-1-yl}-ethoxy)-6-[(vinylcarbonyl)amino]-quinazoline,

(3) 4-[(*R*)-(1-phenylethyl)amino]-7-{2-[4-(2-oxo-tetrahydrofuran-4-yl)-piperazin-1-yl]-ethoxy}-6-[(vinylcarbonyl)amino]-quinazoline and

(4) 4-[(3-chloro-4-fluorophenyl)amino]-7-{2-[4-(2-oxo-tetrahydrofuran-4-yl)-piperazin-1-yl]-ethoxy}-6-[(vinylcarbonyl)amino]-quinazoline,

or a tautomer or salt thereof.

5. A physiologically acceptable salt of a compound according claim 1, 2, 3, or 4, formed with an inorganic or organic acid or base.

6. A pharmaceutical composition containing a compound according claim 1, 2, 3, or 4 or a pharmaeceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

7. A method of treating a benign or malignant tumour, a disease of the respiratory tract or lungs, polyps, a disease of the gastro-intestinal tract, bile duct or gall bladder, a disease of the kidneys or of the skin, which comprises administering a therapeutically effective

amount of a compound according claim 1, 2, 3, or 4 or a pharmaceutically acceptable salt thereof.